Ma. Peeters et al., IN-VIVO FOLIC-ACID SUPPLEMENTATION PARTIALLY CORRECTS IN-VITRO METHOTREXATE TOXICITY IN PATIENTS WITH DOWN-SYNDROME, British Journal of Haematology, 89(3), 1995, pp. 678-680
Patients with Down syndrome have been found to have characteristic in
vivo and in vitro methotrexate toxicity. The in vitro methotrexate tox
icity characteristic of Down syndrome can be diminished by the in vivo
administration of supplemental high doses of folic acid. A possible e
xplanation for the increased sensitivity to methotrexate which has bee
n documented in patients with Down syndrome may be due to imbalances i
n nucleotide pools which result from a gene dosage effect and to great
er methylation demands. Supplemental folic acid may be beneficial by v
irtue of a down-regulation of excess gene activity and may also provid
e needed monocarbons.